You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Find more safety information in the supplementary patient handout How to Safely Take Your Oral Anti-Cancer Medication.

Displaying Drugs List

73 Items
Other Name(s): MabCampath®
Sep 2019
Other Name(s): Agrylin® (Shire Pharma)
Jul 2017
Other Name(s): Vidaza® (Celgene)
Funding:
New Drug Funding Program
  • Azacitidine - Acute Myeloid Leukemia (AML)
  • Azacitidine - Intermediate-2 and high-risk myelodysplastic syndrome (MDS)
Nov 2017
Other Name(s): Treanda® (Lundbeck Canada Inc.)
Funding:
New Drug Funding Program
  • Bendamustine - First Line - Chronic Lymphocytic Leukemia
  • Bendamustine - Relapsed_Refractory - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
  • Bendamustine - First Line - Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Apr 2017
Sep 2019
Other Name(s): Blincyto
Funding:
New Drug Funding Program
  • Blinatumomab - Relapsed or Refractory Acute Lymphoblastic Leukemia
  • Blinatumomab – Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia
Sep 2019
Other Name(s): Velcade®
Funding:
New Drug Funding Program
  • Bortezomib - Previously Untreated - Multiple Myeloma
  • Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
  • Bortezomib - Relapsed or Refractory Multiple Myeloma
Jul 2019
Other Name(s): Bosulif®
Funding:
Exceptional Access Program
  • bosutinib - For the treatment of patients with chronic, accelerated or blast phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML), according to specific criteria.
Jun 2019
Other Name(s): Adcetris®
Funding:
New Drug Funding Program
  • Brentuximab Vedotin – Relapsed or Refractory Hodgkin Lymphoma
  • Brentuximab Vedotin – Systemic Anaplastic Large Cell Lymphoma
  • Brentuximab Vedotin – Consolidation Post-Autologous Stem Cell Transplant (ASCT) for Hodgkin Lymphoma
Dec 2019
Other Name(s): Busulfex®; Myleran®
Funding:
ODB - General Benefit
  • busulfan - oral tablets
Jun 2019
Nov 2019
Other Name(s): Kyprolis ()
Funding:
New Drug Funding Program
  • Carfilzomib (Doublet Therapy) - In Combination with Dexamethasone for Relapsed Multiple Myeloma
  • Carfilzomib (Triplet Therapy) - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma
Oct 2018